TARO-TICAGRELOR TABLET

Țară: Canada

Limbă: engleză

Sursă: Health Canada

Ingredient activ:

TICAGRELOR

Disponibil de la:

TARO PHARMACEUTICALS INC

Codul ATC:

B01AC24

INN (nume internaţional):

TICAGRELOR

Dozare:

90MG

Forma farmaceutică:

TABLET

Compoziție:

TICAGRELOR 90MG

Calea de administrare:

ORAL

Unități în pachet:

15G/50G

Tip de prescriptie medicala:

Prescription

Zonă Terapeutică:

PLATELET AGGREGATION INHIBITORS

Rezumat produs:

Active ingredient group (AIG) number: 0152934001; AHFS:

Statutul autorizaţiei:

APPROVED

Data de autorizare:

2021-03-01

Caracteristicilor produsului

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
TARO-TICAGRELOR
Ticagrelor
Tablets, 60 mg and 90 mg, Oral Use
Taro Standard
Platelet Aggregation Inhibitor
Taro Pharmaceuticals Inc.
130 East Drive
Brampton, ON
L6T 1C1
Date of Initial Authorization:
March 01, 2021
Date of Revision:
June 22, 2023
Submission Control Number: 274174
_Taro-Ticagrelor Product Monograph _
_ _
_Page 2 of 69 _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Cardiovascular
09/2022
7 WARNINGS AND PRECAUTIONS, 7.1.3 Pediatrics
06/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
.................................................................................................................
4
1.1
Pediatrics
........................................................................................................................
4
1.2
Geriatrics.........................................................................................................................
4
2
CONTRAINDICATIONS
...................................................................................................
4
4
DOSAGE AND ADMINISTRATION
...................................................................................
5
4.1
Dosing Considerations
....................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
............................................................... 5
4.4
Administration
................................................................................................................
7
4.5
Missed Dose
................